Первая пятница декабря
Конгресс 2014
Новости офтальмологии
"Want to try something different which past attending surgeons and faculty have really enjoyed? I invite you to Orlando to experience a meeting like no other – exciting, useful, intense and fun – the way education is supposed to be!"
A federal jury has ordered Imprimis Pharmaceuticals to pay $48,500 in damages to Allergan, far less than Allergan was seeking, for lost business due to false advertising by the compounding company. In the lawsuit against Harrow Health Inc., formerly known as Imprimis Pharmaceuticals, Allergan requested damages of more than $7.2 million in lost profits and as much as $54 million in profit disgorgement, according to a Form 8-K filing to the U.S Securities and Exchange Commission by Harrow Health.
Ocular surface disease (OSD) is a group of disorders commonly seen in ophthalmic practice, but it is challenging to differentially diagnose and is frequently undertreated. The consequences of undiagnosed and/or undertreated OSD can impact patient quality of life and severely affect visual acuity, especially in those undergoing cataract and/or refractive surgery. Effective diagnostics and therapeutics have been limited, but recent approvals by the US Food and Drug Administration as well as continued evaluation of new therapy modalities have the potential to enhance outcomes in patients with OSD. In this publication series, Ocular Surface Diseases, Disorders, & Dysfunctions® Volume 4, expert clinicians will review and evaluate pertinent advances in the diagnosis, management, and treatment of OSD, as well as offer clinical expertise for the management of challenging case presentations.
OCT Angiography imaging is a relatively new technology that generates large amounts of clinical information. It is therefore important to define a consistent method of assessing OCT Angiography images to streamline the interpretation and take full advantage of the data generated. This is a short instructional video which teaches a systematic approach to evaluating OCT Angiography images in 8 steps. The video features Christopher Mody, Director of Clinical Affairs, Heidelberg Engineering Limited and Dr. Richard Gale, Consultant Medical Ophthalmologist, York Teaching Hospital NHS Foundation Trust
Purpose: To study self-reported patient satisfaction and dry eye symptoms in hyperopic correction with femtosecond laser-assisted in situ keratomileusis (FS-LASIK).
Glaukos is aiming to tackle the glaucoma market with micro-devices that include the iStent and iDose devices, CEO Tom Burns said at the 37th annual J.P. Morgan Healthcare Conference in San Francisco. “Our mission is aspirational,” he said. “As a company we are seeking to transform glaucoma therapy, and in doing so we want to transform ourselves into a hybrid surgical-pharmaceutical-medical device company that is creating powerful platforms in sustained pharmaceutical therapy, medical devices and diagnostic platforms.”
Вебинары, 23 мая, приблизительно в 17-00 по мск времени. Следим?
Can GATT be an Effective Surgical Option for POAG in Developing Countries?
People with good vision despite having centre-involved diabetic macular oedema can safely forego immediate treatment of their eye condition as long as they are closely monitored, and treatment begins promptly if vision worsens, according to a study published in JAMA.
The SPECTRALIS® High Magnification Module consists of a highly innovative magnifying lens and software. It elegantly demonstrates the capability of confocal scanning laser ophthalmoscopy (cSLO) to resolve ocular microstructures by reducing intraocular light scattering. These ocular microstructures can even be visualized in eyes with cataracts. The image contrast and clarity obtained by combining laser light selectivity with confocal scanning are often not available from fundus photography, highlighting critical diagnostic details not visible on ophthalmoscopy. After a region of interest has been identified using a larger field of view, the user can acquire ~8° magnified images at an enhanced resolution to investigate the area at an even higher level of detail. This possibility may provide unique insight into the progression of certain retinal diseases.
“We at Heidelberg are particularly proud of the collaboration with NASA to have our imaging technology be a part of this mission,” said Arianna Schoess Vargas, CEO. “With this advanced OCT technology, it is easier for the astronauts to capture high-quality images in even less time. Working in such an environment, there is significant value placed on efficiency that doesn’t compromise quality.”
Круглый стол для врачей-офтальмологов «Современные рекомендации ведения глаукомных пациентов с ВМД» Дата проведения 20.02.2019 г. Место проведения: г. Уфа, ул. Аксакова, 4, отель «Хилтон Гарден Инн», конференц-зал «Волга»
Уважаемые коллеги! Приглашаем вас принять участие в онлайн трансляции научно-образовательного вебинара «Новые тенденции в офтальмологии: обзор результатов научных сессий 18-го конгресса Европейского Общества специалистов по сетчатке: EuRetina-2018». Лектор: Измайлов Александр Сергеевич, профессор, д.м.н., заведующий отделением лазерного лечения ФГАУ «НМИЦ «МНТК «Микрохирургия глаза» им. акад. С.Н. Федорова», Санкт-Петербург. Онлайн трансляция начнется 21 февраля 2019 в 16:00 по МСК, пожалуйста, подключайтесь за 5 минут до начала. Чтобы присоединиться к онлайн трансляции мероприятия, пройдите по ссылке: https://novartis-2019.adobeconnect.com/euretina2018/ Дополнительного программного обеспечения для просмотра на компьютере не требуется, ссылка автоматически откроется в браузере. Если Вы используете планшет или мобильный телефон, то желательно установить бесплатное приложение Adobe Connect.
Objective: To assess outcomes in treatment-naive eyes with neovascular age-related macular degeneration (nAMD) and good baseline visual acuity (VA) treated using a treat-and-extend (T&E) regimen with intravitreal aflibercept, ranibizumab, or bevacizumab.
Eyenovia announced the FDA accepted an investigational new drug application to initiate a phase 3 registration trial of MicroPine to reduce the progression of myopia in children. According to a company press release, the U.S.-based, multicenter, randomized, double-masked CHAPERONE study will include 400 children between 5 and 12 years old. Participants will be randomly assigned to receive one of two MicroPine treatment concentrations or a placebo.
Приказ Министерства здравоохранения РФ от 28 февраля 2019 г. № 103н "Об утверждении порядка и сроков разработки клинических рекомендаций, их пересмотра, типовой формы клинических рекомендаций и требований к их структуре, составу и научной обоснованности включаемой в клинические рекомендации информации”.
Что "заставляет" Вас заниматься научными исследованиями?
Популярная пресса
Интересное видео
Клуб молодых офтальмологов

МОО "Глаукомное общество"

Экспертный совет по глаукоме

Диабет. Рекомендации

Глаукома. Рекомендации ICO

Новостная лента на Twitter
Новости зарубежной офтальмологии